No Data
No Data
Roche (RHHBY.US) oral PI3Kα inhibitor "Inalise" has been approved for sale in China.
On March 14, Roche (RHHBY.US) announced that the PI3Kα inhibitor "Inalise" has been approved for market.
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
FDA Commissioner Nominee Makary Advances to Full Senate Vote
Trump's Chips War Has Left Intel's New CEO With a -2-
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Beam Therapeutics (BEAM)
Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk